Scientists outline nuclear winter scenario
The aftermath following an exchange of nukes could include prolonged cooling, agricultural collapse and social upheaval, a study has said
Apart from killing millions, a war between Russia and the US could result in a 'nuclear winter' that would devastate the Earth's atmosphere and lead to a drastic reduction in agricultural production, a group of American scientists has said.
A team led by an assistant research professor at Pennsylvania State University, Yuning Shi, published the results of their stimulation of a war between the two largest nuclear powers in an article in Environmental Research Letters earlier this month.
According to the paper, "a global nuclear war" could see up to 150 million tons of soot released into the atmosphere, leading to "prolonged cooling, agricultural collapse, and social upheaval on an unprecedented scale."
In such a scenario, precipitation and solar radiation would decrease by as much as 70% globally, resulting in the average air temperature dropping by over 15 degrees Celsius, it said.
Due to this 'nuclear winter', the annual production of maize, which the scientists focused on, could decrease by as much as 80%, the paper said.
Supply chains and trade could also be seriously disrupted, further worsening the situation in the agricultural sector and leading to regional or global famine, the researchers stressed. According to their estimates, it would take from seven to 12 years to restore food production levels.
Understanding the possible damage from a nuclear exchange and preparing for it is "critical" given current geopolitical trends, including the Ukraine conflict, the tensions between India and Pakistan, and instability in the Middle East that have "undermined the fragile detente that prevailed during the last years of the Cold War," the paper stressed.
Shi and his colleagues proposed to develop what they called 'Agricultural Resilience Kits' of region- and climate-specific seeds and technology packages to serve as a "buffer against uncertainty" in case of a 'nuclear winter'.
Last month, Nikolay Patrushev, national security adviser to President Vladimir Putin, accused Western powers of "deploying their military machine against Russia and becoming delirious with nuclear apocalypse scenarios."
Moscow has repeatedly denied claims by the US and EU of planning to use nuclear weapons during the Ukraine conflict. However, Russia updated its nuclear doctrine in 2023, allowing for the use of such arms as a deterrent to prevent aggression by hostile powers and military blocs that possess weapons of mass destruction or large arsenals of conventional weapons.
(RT.com)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
an hour ago
- Mint
Immunotherapy Drugs Show Major Progress in Early-Stage Cancer
(Bloomberg) -- Drugs that boost the body's immune system to fight disease are showing promise in treating a variety of cancers in earlier stages, a development primed to expand their use and transform care for stubborn diseases like gastric and colon cancer. Immunotherapy treatments such as Opdivo from Bristol Myers Squibb Co., Imfinzi from AstraZeneca PLC, and Roche Holding AG's Tecentriq have become bestsellers by increasing survival times in a number of advanced cancers. Now the treatments are showing success against early and mid-stage cancers, according to results of large trials being presented at the American Society of Clinical Oncology meeting in Chicago this weekend. One highlight is that the drugs are preventing recurrences in operable tumors that are at high risk of relapsing. 'We're learning that immunotherapy may, in fact, be more effective when you have less of a tumor burden,' said Jean Bourhis, an oncologist at Lausanne University Hospital in Switzerland, who led a study on patients with squamous cell carcinoma of the head and neck. 'The key is using it earlier.' Treatment for that kind of head and neck cancer hasn't fundamentally changed in two decades. Use of Bristol's Opdivo in the study slashed the recurrence rate by nearly a quarter after three years when used after surgery to help prevent a relapse. This development could impact about 40% of people diagnosed with the disease, Bourhis said. In a study sponsored by AstraZeneca, researchers found that using the firm's Imfinzi drug before and after surgery reduced the odds by 29% over a two-year period that a nasty type of operable gastric or gastroesophageal junction cancer would relapse or progress. The development sets the stage for a new global standard of care for such cancers, which are particularly common in Asia, doctors said. In a study on colon cancer, sponsored by the National Cancer Institute, oncologists found that adding Roche's Tecentriq to standard chemotherapy used after surgery significantly bolstered the number of patients who were alive and disease free after three years. The finding represents a major advance in the field, the study's lead investigator said, and could help roughly 15% of patients with operable colon cancer that has spread to the lymph nodes. 'We have a real potential to cure many of these patients,' the investigator, Mayo Clinic oncologist Frank Sinicrope, said in an interview. For the companies, expanding the use of immune drugs to earlier stage cancers may provide a new source of revenue to an aging group of blockbusters. 'This brings a commercial opportunity,' said Susan Galbraith, AstraZeneca's executive vice president for oncology research. The company has discussed with regulators the potential for the drug to get approved for the new use case, she said, declining to go into detail of where those talks stood. Merck & Co.'s immunotherapy Keytruda, which is featured in multiple studies at ASCO, shows how lucrative treating disease early can be. It has become the world's best-selling medicine thanks in part to its use in early cancer. Of the drug's 41 approved uses, nine are now for early-stage disease. Treating cancer early is 'where our growth is,' Dean Li, head of research at Merck, said Thursday at an investor conference. 'But it's not just economic growth. This is where you can cure patients.' New immunotherapy results in head and neck cancer are poised to upend decades of medical practice. For patients with an aggressive form of head and neck cancer, the longstanding first-line treatment was to surgically remove the tumor and use chemotherapy and radiation to keep the disease at bay. The Opdivo study showed that adding the drug to the standard of care cut the risk of cancer recurrence three years after treatment by 24%. That finding comes on the heels of a successful head and neck study from Merck's rival Keytruda drug. In a big study presented in April, Keytruda reduced the risk of relapse when it was used both before and after surgery in head and neck patients. That potential new use is now under review by US regulators. In AstraZeneca's study being presented at ASCO, using Imfinzi before and after surgery was able to increase the number of people alive without a recurrence or disease progression after two years to 67.4% from 58.5%. 'For patients facing a high risk of relapse, this brings new hope for long-term survival,' said Yelena Y. Janjigian, an oncologist at New York's Memorial Sloan Kettering Cancer Center, who was lead investigator on the study. 'It is a pretty big deal.' Will Murray, a 52-year-old retired New York police detective, discovered he had a tumor at the junction of his esophagus and stomach in April 2022. It was operable, but he was at high risk of relapse. In an interview, he said the high death rate from this type of cancer terrified him. But Murray received one of the last spots in the AstraZeneca study and got into the immunotherapy arm. His tumor started shrinking even before the surgery. And since the operation, it hasn't come back, although he did suffer thyroid deficiency, a side effect of immune therapy drugs. Murray now has to eat carefully and can't sleep flat due to the stomach operation, but he can mostly live a normal life, including taking long walks and going on trips with his girlfriend. He credits the immunotherapy treatment trial for helping keep his tumors at bay. 'It saved my life,' Murray said. --With assistance from Danielle Chaves. More stories like this are available on
India.com
2 hours ago
- India.com
What will happen If Earth's temperature rises by just 2 degrees Celsius? These places will...
Our planet Earth is truly amazing. It's the only home we have, providing everything we need to survive, including air, water, food, shelter, and biodiversity. Have you ever wondered what would happen if the global temperature rises by two degrees Celsius? According to a new scientific study, the Hindu Kush Himalaya, an important water source for nearly two billion people, could lose up to 75 per cent of its glacier ice by the end of this century if global temperatures rise by 2 degrees Celsius above pre-industrial levels. It is important to note that the glaciers in the Hindu Kush mountains are the source of many rivers, which receive their water from the glaciers and support the livelihoods of two billion people. A study published in the scientific journal Science states that if countries can limit the rise in temperature to 1.5 degrees Celsius above pre-industrial levels, around 40–45% of the glacier ice in the Himalayas and the Caucasus Mountains could be preserved. In contrast, the study found that if global temperatures rise by 2.7 degrees Celsius by the end of this century, only about one-quarter of the world's glacier ice will remain. 'We estimate that glaciers globally will lose 39 (range, 15 to 55)% of their mass relative to 2020, corresponding to a global mean sea-level rise of 113 (range, 43 to 204) mm even if temperatures stabilized at present-day conditions. Under the +1.5°C Paris Agreement goal, more than twice as much global glacier mass remains at equilibration (53% versus 24%) compared with the warming level resulting from current policies (+2.7°C by 2100 above preindustrial),' reads the abstract of the study. The study states that glacier regions most important to human communities, such as the European Alps, the mountain ranges of western North America and Canada, and Iceland, will be especially hard hit. At a global temperature rise of two degrees Celsius, these regions could lose nearly all of their ice, with only about 10–15 percent of the 2020 ice levels remaining. The study reads, 'If global temperatures stabilize at the limits targeted in the Paris Agreement, then glaciers are projected to eventually lose 47% (range, 20 to 64%) of their global mass relative to 2020 for a +1.5°C scenario and 63% (range, 43 to 76%) for a +2.0°C scenario, contributing 138 mm (range, 59 to 237 mm) and 190 mm (range, 128 to 279 mm) to global mean sea-level rise, respectively (all values at steady state). Under current climate policy pledges, global temperatures are projected to reach 2.7°C above preindustrial levels by 2100 (30), which would result in eventually losing 76% (range, 54 to 82%) of glacier mass globally, corresponding to 230 mm (range, 159 to 302 mm) of sea-level rise. Thus, more than twice as much global glacier mass is projected to remain long term under the Paris Agreement +1.5°C goal compared with current climate policies.' The outlook for the Scandinavian mountains appears even more dire, with forecasts suggesting that glaciers in the region could lose all their ice at this temperature level. The study emphasizes that keeping the global temperature increase within the 1.5°C limit set by the 2015 Paris Agreement could aid in retaining some glacier ice in all affected areas. While speaking at the conference, Asian Development Bank Vice-President Yingming Yang said. 'Melting glaciers threaten lives on an unprecedented scale, including the livelihoods of more than 2 billion people in Asia. Switching to clean energy to cut the release of planet-warming emissions remains the most effective way of slowing glacial melt'.
NDTV
11 hours ago
- NDTV
Viral Video Of Chinese Paraglider's Accidental 8,000-Metre Flight Might Be AI-Generated
A viral video of a Chinese paraglider accidentally being propelled more than 8,000 metres high by an updraft has been found to be generated by artificial intelligence, at least partially, according to a report in NBC News. 55-year-old Peng Yujiang claimed that he was paragliding at approximately 3,000 metres, but the unexpected conditions carried him nearly 5,000 metres higher. He endured temperatures around -40 degrees Celsius and dangerously low oxygen levels. Despite experiencing hypoxia and severe frostbite, Mr Peng managed to remain conscious and safely navigated back to the ground. However, the investigation reveals that the first five seconds of the video might be AI-generated. In the clip, Mr Peng can be seen gliding at high altitude with his legs dangling, but the footage is seemingly cropped. The crop omitted a logo belonging to Doubao AI, suggesting it was likely created by the ByteDance-owned company's AI tool. The same portion of the video was uploaded separately to Facebook on May 25 with the company's watermark. "It's unclear if the remaining footage of Peng gliding through the sky which differs from the first five seconds is authentic or not," the publication stated. GetReal Labs, an AI-verification company, corroborated the claims, stating that the analysis of the footage yielded proof of AI use. "We were able to extract a few frames and analyze them using our Inspect platform, and our models confirm that the images are synthetic," said GetReal Labs, adding that several other elements in the video differed from the rest of the footage. News agency Reuters, which distributed the clip without the AI logo has taken down the video. Other news outlet have also removed their versions of the video. "We have reason to believe this is an AI-generated video and are currently working on killing this footage," Reuters said. Peng banned Notably, Mr Peng was testing secondhand paragliding equipment when the alleged incident took place. The video clip instantly went viral on social media with users lauding him for keeping calm. "I had just bought a second-hand paragliding harness and wanted to test it, so I was conducting ground parachute shaking. After a while, the wind suddenly picked up and lifted me into the air. I tried to land as soon as possible, but I failed," Mr Peng told the Chinese media. Mr Peng and his friend, who posted the video, received six-month bans from paragliding activities due to unauthorised flight and safety violations.
